Cox-2 inhibition (Celebrex 200 mg bid) added to standard chemoRx (FolFox) in pts w/ stage III colon cancer failed to improve survival at 3 yrs - DB, RCT vs placebo; 3 yrs Dz free survival was Celecoxib 76% vs PBO 73% (HR 0.89; 95% CI, 0.76-1.03; P = .12) https://t.co/81L33QLa9d https://t.co/EQXgwMcgtd